What metrics would you use to evaluate Amgen's Repatha cholesterol-lowering medication?

Introduction

Evaluating the success of Amgen's Repatha cholesterol-lowering medication requires a comprehensive approach to product metrics. As a cholesterol-lowering drug, Repatha's performance impacts multiple stakeholders, from patients and healthcare providers to insurers and Amgen itself. I'll follow a structured framework that covers core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Repatha (evolocumab) is a PCSK9 inhibitor developed by Amgen to lower LDL cholesterol in patients with high cholesterol, particularly those with familial hypercholesterolemia or atherosclerotic cardiovascular disease. It's administered via subcutaneous injection every two or four weeks.

Key stakeholders include:

1. Patients: Seeking effective cholesterol management with minimal side effects
2. Healthcare providers: Looking for reliable treatment options for high-risk patients
3. Insurers: Concerned with cost-effectiveness and long-term health outcomes
4. Amgen: Aiming for market share, revenue growth, and return on R&D investment

User flow:

1. Prescription: Healthcare provider assesses patient and prescribes Repatha
2. Insurance approval: Insurer reviews and approves coverage
3. Administration: Patient receives injection at home or healthcare facility
4. Monitoring: Regular check-ups to assess cholesterol levels and overall health

Repatha fits into Amgen's broader strategy of developing innovative biologic therapies for serious illnesses. It competes with other PCSK9 inhibitors like Praluent (alirocumab) from Sanofi/Regeneron, as well as traditional statins.

Product Lifecycle Stage: Repatha is in the growth stage, having been on the market since 2015 but still expanding its user base and indications.

Physical Product Considerations:

• Distribution channels: Specialty pharmacies and healthcare facilities
• Shelf-life: Requires refrigeration and has a limited shelf life
• Sales model: Prescription-only, often requiring prior authorization from insurers